Related Experiment Video
Updated: Aug 1, 2025
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Human adenovirus type 7 subunit vaccine induces dendritic cell maturation through the TLR4/NF-κB pathway is highly
Yaru Li1,2, Xia Yang2, Renshuang Zhao2
1Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, China.
Insights
A new recombinant subunit vaccine (rBV-hexon) shows potential against human adenovirus type 7 (HAdv-7). This vaccine effectively stimulates immune responses, offering a promising candidate for HAdv-7 prevention.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Human adenovirus type 7 (HAdv-7) is a significant cause of respiratory infections in children, with no current vaccines or treatments.
- The urgent need for effective HAdv-7 interventions necessitates the development of novel vaccine strategies.
Purpose of the Study:
- To develop and evaluate a recombinant subunit vaccine expressing the HAdv-7 hexon protein (rBV-hexon).
- To assess the vaccine's ability to induce humoral and cellular immune responses for HAdv-7 prevention.
Main Methods:
- Utilized a baculovirus-insect cell expression system to produce the rBV-hexon subunit vaccine.
- Evaluated vaccine efficacy by analyzing antigen-presenting cell markers, cytokine secretion, neutralizing antibody levels, and T cell activation.
Main Results:
- The rBV-hexon vaccine promoted dendritic cell maturation and antigen uptake via the TLR4/NF-κB pathway.
- Upregulation of MHCI, CD80, CD86, and cytokines was observed.
- The vaccine successfully induced strong neutralizing antibody and cellular immune responses, including T lymphocyte activation.
Conclusions:
- The rBV-hexon recombinant subunit vaccine effectively stimulates both humoral and cellular immunity.
- This vaccine demonstrates significant potential as a future preventative measure against HAdv-7 infections.
Introduction:
Human adenovirus type 7 (HAdv-7) infection is the main cause of upper respiratory tract infection, bronchitis and pneumonia in children. At present, there are no anti- adenovirus drugs or preventive vaccines in the market. Therefore, it is necessary to develop a safe and effective anti-adenovirus type 7 vaccine.
Methods:
In this study, In this study, we used the baculovirus-insect cell expression system to design a recombinant subunit vaccine expressing adenovirus type 7 hexon protein (rBV-hexon) to induce high-level humoral and cellular immune responses. To evaluate the effectiveness of the vaccine, we first detected the expression of molecular markers on the surface of antigen presenting cells and the secretion of proinflammatory cytokines in vitro. We then measured the levels of neutralizing antibodies and T cell activation in vivo.
Results:
The results showed that the rBV-hexon recombinant subunit vaccine could promote DC maturation and improve its antigen uptake capability, including the TLR4/NF-κB pathway which upregulated the expression of MHCI, CD80, CD86 and cytokines. The vaccine also triggered a strong neutralizing antibody and cellular immune response, and activated T lymphocytes.
Discussion:
Therefore, the recombinant subunit vaccine rBV-hexon promoted promotes humoral and cellular immune responses, thereby has the potential to become a vaccine against HAdv-7.
Related Concept Videos
01:51Vaccinations
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...